论文部分内容阅读
目的 :探讨肾康注射液 (SKI)阻抑肾小球硬化 (GS)、防治慢性肾功能衰竭 (CRF)的部分作用机理 ,为SKI临床应用提供依据。方法 :采用放射免疫检测技术 ,观察SKI对体外培养人肾小球系膜细胞 (GMC)自分泌内皮素 1(ET 1)、一氧化氮 (NO)水平的影响。结果 :SKI及其含药血清明显抑制GMC自分泌ET 1(P <0 .0 1、P <0 .0 5)、促进其自分泌NO(P <0 .0 5) ,有量效依赖性 ;与肝素合用 ,协同抑制GMC自分泌ET 1水平 (P <0 .0 5)。结论 :SKI对GMC自分泌ET 1、NO的调节作用是其阻抑GS、防治CRF的重要机制之一。SKI对ET 1的抑制效应、对NO的促进作用是其活血益气功效的具体形式之一。
Objective: To explore the mechanism of action of Shenkang injection (SKI) in inhibiting glomerulosclerosis (GS) and preventing and treating chronic renal failure (CRF), and provide basis for clinical application of SKI. METHODS: Radioimmunoassay was used to observe the effect of SKI on autocrine endothelin-1 (ET 1) and nitric oxide (NO) levels in cultured glomerular mesangial cells (GMC). RESULTS: SKI and its drug-containing serum significantly inhibited autocrine ET 1 (P <0.01, P <0.05), and promoted autocrine NO (P <0.05), which was dose-dependent. ; Combined with heparin, synergistic inhibition of GMC autocrine ET 1 levels (P <0.05). Conclusion : The regulation effect of SKI on the autocrine ET 1 and NO of GMC is one of the important mechanisms for inhibiting GS and preventing CRF. The inhibitory effect of SKI on ET 1 and the promotion of NO are one of the specific forms of its efficacy in promoting blood circulation and qi.